Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Multicenter, Open-label, Phase II Study in Patients With Immunoglobulin M Monoclonal Gammopathy of Unknown Significance and Myelin Associated Glycoprotein Antibodies Related Polyneuropathy and Zanubrutinib Treatment - MAGNAZ Trial

NCT05939037 is registered in ClinicalTrials.gov with UMC Utrecht as lead sponsor.

NCT NCT05939037
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05939037 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Multicenter, Open-label, Phase II Study in Patients With Immunoglobulin M Monoclonal Gammopathy of Unknown Significance and Myelin Associated Glycoprotein Antibodies Related Polyneuropathy and Zanubrutinib Treatment - MAGNAZ Trial
Lead sponsor
UMC Utrecht
Phase
Phase 2
Overall status
Active, not recruiting
Start date
March 1, 2024
Completion date
March 1, 2029
Enrollment
35 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

monoclonal gammopathy of uncertain significance